Barinthus Biotherapeutics plc. financial data

Symbol
BRNS on Nasdaq
Industry
Pharmaceutical Preparations
Location
Unit 6 10, Zeus Building, Rutherford Avenue, Harwell, Didcot, United Kingdom
State of incorporation
United Kingdom
Fiscal year end
December 31
Former names
Vaccitech plc (to 10/5/2023), Vaccitech Ltd (to 3/23/2021)
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.01K % -37.6%
Debt-to-equity 16.8 % +36.5%
Return On Equity -35.9 % -53.2%
Return On Assets -30.7 % -47.3%
Operating Margin -490 % -1791%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 39.4M shares +2.31%
Common Stock, Shares, Outstanding 39.2M shares +1.71%
Entity Public Float 79.4M USD -52.1%
Common Stock, Value, Issued 1K USD 0%
Weighted Average Number of Shares Outstanding, Basic 39M shares +1.65%
Weighted Average Number of Shares Outstanding, Diluted 39M shares +1.65%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 44.3M USD -2.17%
General and Administrative Expense 7.2M USD -45.1%
Operating Income (Loss) -71.3M USD -8.43%
Nonoperating Income (Expense) 5.96M USD -7.08%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -65.3M USD -10.1%
Income Tax Expense (Benefit) -1.47M USD +66.2%
Net Income (Loss) Attributable to Parent -63.8M USD -16.1%
Earnings Per Share, Basic -1.64 USD/shares -13.1%
Earnings Per Share, Diluted -1.64 USD/shares -13.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 142M USD -26.9%
Accounts Receivable, after Allowance for Credit Loss, Current 172K USD -99%
Other Assets, Current 626K USD -56.7%
Assets, Current 132M USD -28.6%
Property, Plant and Equipment, Net 11M USD -20.2%
Operating Lease, Right-of-Use Asset 7.29M USD -5.46%
Intangible Assets, Net (Excluding Goodwill) 23.5M USD -11.8%
Goodwill 12.2M USD 0%
Assets 187M USD -24.1%
Accounts Payable, Current 2.56M USD +5.23%
Contract with Customer, Liability, Current 111K USD -43.4%
Liabilities, Current 15.6M USD +28.7%
Deferred Income Tax Liabilities, Net 11.8M USD -7.33%
Operating Lease, Liability, Noncurrent 10.7M USD -3.53%
Other Liabilities, Noncurrent 1.34M USD +2.92%
Liabilities 30M USD +4.51%
Retained Earnings (Accumulated Deficit) -209M USD -43.9%
Stockholders' Equity Attributable to Parent 157M USD -27.9%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 157M USD -27.9%
Liabilities and Equity 187M USD -24.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -11.8M USD -272%
Net Cash Provided by (Used in) Financing Activities 503K USD -70.2%
Net Cash Provided by (Used in) Investing Activities -308K USD +87.7%
Common Stock, Shares Authorized 39.2M shares +1.71%
Common Stock, Shares, Issued 39.2M shares +1.71%
Common Stock, Par or Stated Value Per Share 0 GBP/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -12.1M USD -296%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 118M USD -31.9%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD
Deferred Tax Assets, Valuation Allowance 25.1M USD +82.8%
Deferred Tax Assets, Gross 36.2M USD +60%
Operating Lease, Liability 12.6M USD +3.21%
Depreciation 2.7M USD +68.8%
Payments to Acquire Property, Plant, and Equipment 308K USD -87.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -65.2M USD -38.8%
Lessee, Operating Lease, Liability, to be Paid 16.8M USD -3.12%
Property, Plant and Equipment, Gross 15.5M USD +67.1%
Operating Lease, Liability, Current 1.92M USD +68.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.95M USD +0.93%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.93M USD +8.19%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Deferred Income Tax Expense (Benefit) -37K USD +92.8%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 4.23M USD -18.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.98M USD +0.97%
Deferred Tax Assets, Operating Loss Carryforwards 23.6M USD +137%
Lessee, Operating Lease, Liability, to be Paid, Year Four 2M USD +1.01%
Operating Lease, Payments 346K USD +57.3%
Additional Paid in Capital 390M USD +1.2%
Amortization of Intangible Assets 3.2M USD 0%
Depreciation, Depletion and Amortization 1.43M USD +17.1%
Deferred Tax Assets, Net of Valuation Allowance 11.2M USD +25.1%
Share-based Payment Arrangement, Expense 3.65M USD -50.3%
Interest Expense 12K USD